Emergent BioSolutions Inc
EBS12.430USD
-0.200-1.58%
Handelsschluss 12/26, 16:00（ET）Kurse um 15 Minuten verzögert
655.06MMarktkapitalisierung
8.75KGV TTM
mehr Informationen über Emergent BioSolutions Inc Unternehmen
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.
Emergent BioSolutions Inc Informationen
BörsenkürzelEBS
Name des UnternehmensEmergent BioSolutions Inc
IPO-datumNov 15, 2006
CEOPapa (Joseph C)
Anzahl der mitarbeiter900
WertpapierartOrdinary Share
GeschäftsjahresendeNov 15
Addresse300 Professional Dr
StadtGAITHERSBURG
BörseNASDAQ OMX NASDAQ Basic NYSE
LandUnited States of America
Postleitzahl20879
Telefon12406313200
Websitehttps://emergentbiosolutions.com/
BörsenkürzelEBS
IPO-datumNov 15, 2006
CEOPapa (Joseph C)
Führungskräfte von Emergent BioSolutions Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Joseph C. (Joe) Papa
Mr. Joseph C. (Joe) Papa
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
342.50K
+21.24%
Mr. Richard S. (Rich) Lindahl
Mr. Richard S. (Rich) Lindahl
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
196.50K
-2.48%
Dr. Zsolt Harsanyi, Ph.D.
Dr. Zsolt Harsanyi, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
103.49K
+49.80%
Dr. Simon C Lowry, M.D.
Dr. Simon C Lowry, M.D.
Chief Medical Officer, Head of Research and Development
Chief Medical Officer, Head of Research and Development
91.98K
+211.99%
Ms. Coleen Glessner
Ms. Coleen Glessner
Executive Vice President - Quality and Ethics and Compliance
Executive Vice President - Quality and Ethics and Compliance
90.86K
-25.20%
Mr. Ronald B. Richard
Mr. Ronald B. Richard
Independent Director
Independent Director
78.17K
-8.33%
Ms. Jessica Perl
Ms. Jessica Perl
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
68.39K
+1061.66%
Mr. Marvin L. White
Mr. Marvin L. White
Independent Director
Independent Director
68.25K
+101.64%
Mr. Keith A. Katkin, CPA
Mr. Keith A. Katkin, CPA
Independent Director
Independent Director
66.14K
-10.60%
Mr. William Hartzel
Mr. William Hartzel
Senior Vice President - Manufacturing and Bioservices
Senior Vice President - Manufacturing and Bioservices
62.55K
-0.97%
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Joseph C. (Joe) Papa
Mr. Joseph C. (Joe) Papa
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
342.50K
+21.24%
Mr. Richard S. (Rich) Lindahl
Mr. Richard S. (Rich) Lindahl
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
196.50K
-2.48%
Dr. Zsolt Harsanyi, Ph.D.
Dr. Zsolt Harsanyi, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
103.49K
+49.80%
Dr. Simon C Lowry, M.D.
Dr. Simon C Lowry, M.D.
Chief Medical Officer, Head of Research and Development
Chief Medical Officer, Head of Research and Development
91.98K
+211.99%
Ms. Coleen Glessner
Ms. Coleen Glessner
Executive Vice President - Quality and Ethics and Compliance
Executive Vice President - Quality and Ethics and Compliance
90.86K
-25.20%
Mr. Ronald B. Richard
Mr. Ronald B. Richard
Independent Director
Independent Director
78.17K
-8.33%
Umsatzaufteilung
Währung: USDAktualisiert: Mon, Oct 6
Währung: USDAktualisiert: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Commercial Product sales
67.50M
47.91%
MCM Product sales
58.40M
41.45%
Contracts and grants
15.00M
10.65%
Nach RegionUSD
Name
Umsatz
Anteil
Non-U.S Government
83.10M
58.98%
U.S.Government
57.80M
41.02%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Commercial Product sales
67.50M
47.91%
MCM Product sales
58.40M
41.45%
Contracts and grants
15.00M
10.65%
Aktionärsstatistik
Aktualisiert: Mon, Nov 17
Aktualisiert: Mon, Nov 17
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
7.43%
The Vanguard Group, Inc.
6.74%
State Street Investment Management (US)
4.66%
American Century Investment Management, Inc.
4.54%
Dimensional Fund Advisors, L.P.
4.08%
Andere
72.56%
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
7.43%
The Vanguard Group, Inc.
6.74%
State Street Investment Management (US)
4.66%
American Century Investment Management, Inc.
4.54%
Dimensional Fund Advisors, L.P.
4.08%
Andere
72.56%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
34.85%
Investment Advisor/Hedge Fund
30.34%
Hedge Fund
7.25%
Individual Investor
2.97%
Research Firm
1.58%
Pension Fund
1.08%
Bank and Trust
0.83%
Sovereign Wealth Fund
0.18%
Family Office
0.07%
Andere
20.85%
Institutionelle Beteiligung
Aktualisiert: Mon, Dec 8
Aktualisiert: Mon, Dec 8
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
378
39.86M
83.14%
+128.30K
2025Q3
417
39.73M
84.87%
+2.04M
2025Q2
439
37.58M
87.40%
+1.14M
2025Q1
454
36.44M
84.55%
-9.64M
2024Q4
461
35.04M
82.31%
+2.84M
2024Q3
467
32.21M
81.37%
+1.29M
2024Q2
485
30.86M
99.60%
-5.54M
2024Q1
494
36.44M
103.37%
-17.72M
2023Q4
512
41.89M
103.68%
-1.06M
2023Q3
563
42.52M
113.85%
-6.21M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
BlackRock Institutional Trust Company, N.A.
3.83M
7.18%
+2.25M
+141.83%
Jun 30, 2025
The Vanguard Group, Inc.
3.58M
6.72%
+370.21K
+11.52%
Jun 30, 2025
State Street Investment Management (US)
1.74M
3.26%
+30.01K
+1.75%
Jun 30, 2025
American Century Investment Management, Inc.
2.29M
4.3%
-5.46K
-0.24%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
1.85M
3.47%
+252.40K
+15.81%
Jun 30, 2025
Palisade Capital Management, LLC
1.10M
2.06%
-41.83K
-3.66%
Jun 30, 2025
Charles Schwab Investment Management, Inc.
1.11M
2.07%
+521.91K
+89.48%
Jun 30, 2025
Geode Capital Management, L.L.C.
1.28M
2.4%
+666.71K
+108.89%
Jun 30, 2025
Acadian Asset Management LLC
974.59K
1.83%
+141.27K
+16.95%
Jun 30, 2025
Connor, Clark & Lunn Investment Management Ltd.
986.67K
1.85%
+55.05K
+5.91%
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
AdvisorShares Insider Advantage ETF
0.97%
Royce Quant Small-Cap Quality Value ETF
0.41%
State Street SPDR S&P Biotech ETF
0.28%
Federated Hermes MDT Small Cap Core ETF
0.23%
Harbor Human Capital Factor US Small Cap ETF
0.19%
Direxion Daily S&P Biotech Bull 3X Shares
0.18%
Pacer US Small Cap Cash Cows ETF
0.16%
Invesco RAFI US 1500 Small-Mid ETF
0.15%
Avantis US Small Cap Value ETF
0.14%
iShares Micro-Cap ETF
0.13%
Mehr Anzeigen
AdvisorShares Insider Advantage ETF
Anteil0.97%
Royce Quant Small-Cap Quality Value ETF
Anteil0.41%
State Street SPDR S&P Biotech ETF
Anteil0.28%
Federated Hermes MDT Small Cap Core ETF
Anteil0.23%
Harbor Human Capital Factor US Small Cap ETF
Anteil0.19%
Direxion Daily S&P Biotech Bull 3X Shares
Anteil0.18%
Pacer US Small Cap Cash Cows ETF
Anteil0.16%
Invesco RAFI US 1500 Small-Mid ETF
Anteil0.15%
Avantis US Small Cap Value ETF
Anteil0.14%
iShares Micro-Cap ETF
Anteil0.13%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Emergent BioSolutions Inc?
Die fünf größten Anteilseigner von Emergent BioSolutions Inc sind:
BlackRock Institutional Trust Company, N.A. hält 3.83M Aktien, was 7.18% der Gesamtaktien entspricht.
The Vanguard Group, Inc. hält 3.58M Aktien, was 6.72% der Gesamtaktien entspricht.
State Street Investment Management (US) hält 1.74M Aktien, was 3.26% der Gesamtaktien entspricht.
American Century Investment Management, Inc. hält 2.29M Aktien, was 4.30% der Gesamtaktien entspricht.
Dimensional Fund Advisors, L.P. hält 1.85M Aktien, was 3.47% der Gesamtaktien entspricht.
BlackRock Institutional Trust Company, N.A. hält 3.83M Aktien, was 7.18% der Gesamtaktien entspricht.
The Vanguard Group, Inc. hält 3.58M Aktien, was 6.72% der Gesamtaktien entspricht.
State Street Investment Management (US) hält 1.74M Aktien, was 3.26% der Gesamtaktien entspricht.
American Century Investment Management, Inc. hält 2.29M Aktien, was 4.30% der Gesamtaktien entspricht.
Dimensional Fund Advisors, L.P. hält 1.85M Aktien, was 3.47% der Gesamtaktien entspricht.
Was sind die drei wichtigsten Anteilseigner-Typen von Emergent BioSolutions Inc?
Die drei wichtigsten Anteilseigner-Typen von Emergent BioSolutions Inc sind:
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
State Street Investment Management (US)
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
State Street Investment Management (US)
Wie viele Institutionen halten Anteile an Emergent BioSolutions Inc (EBS)?
Mit Stand vom 2025Q4 halten 378 Institutionen Anteile an Emergent BioSolutions Inc, mit einem Gesamtmarktwert von etwa 39.86M, was 83.14% der Gesamtanteile entspricht. Im Vergleich zum 2025Q3 ist der institutionelle Aktienbesitz um -1.74% gestiegen.
Was ist die größte Einnahmequelle von Emergent BioSolutions Inc?
Am FY2025Q2 erzielte das Geschäft mit Commercial Product sales für Emergent BioSolutions Inc den höchsten Umsatz in Höhe von 67.50M, was 47.91% des Gesamtumsatzes entspricht.
